Evoke Pharma
EVOK
EVOK was delisted on the 16th of December, 2025.
9 hedge funds and large institutions have $117K invested in Evoke Pharma in 2022 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 6 reducing their positions, and 3 closing their positions.
0.02% less ownership
Funds ownership: 0.18% → 0.16% (-0.02%)
25% less funds holding
Funds holding: 12 → 9 (-3)
49% less capital invested
Capital invested by funds: $228K → $117K (-$111K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 6
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12.7K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$4.04K |
| 3 |
Citigroup
New York
|
-$3K |
| 4 |
Group One Trading
Chicago,
Illinois
|
-$1.12K |
| 5 |
BlackRock
New York
|
-$789 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $56K | -$4.04K | -123 | -5% |
|
2
Geode Capital Management
Boston,
Massachusetts
| $39K | – | – | – |
|
|
3
BlackRock
New York
| $15K | -$789 | -24 | -3% |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $4K | -$427 | -13 | -7% |
|
|
5
UBS Group
Zurich,
Switzerland
| $2K | -$12.7K | -385 | -81% |
|
|
6
Group One Trading
Chicago,
Illinois
| $1K | -$1.12K | -34 | -55% |
|
|
FDCDDQ
7
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
| $9 | – | – | – |
|
|
8
Citigroup
New York
| – | -$3K | -68 | Closed |
|
9
Wells Fargo
San Francisco,
California
| – | -$33 | -1 | -50% |
|
EVOK Hedge Fund Activity: Q3 2022 in Review
9 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Evoke Pharma (EVOK) for Q3 2022, worth a combined $117K — down 49% from $228K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of EVOK and 0 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 0 added.
The largest seller was UBS Group, cutting an estimated $12.7K.
- 9 institutional investors held Evoke Pharma (EVOK) as of Q3 2022, down from 12 in Q2 2022.
- Funds reported $117K of Evoke Pharma stock for Q3 2022, down 49% quarter-over-quarter.
- 0 funds opened new Evoke Pharma positions in Q3 2022 and 3 closed out, a net change of -3 holders.
- The largest Evoke Pharma seller in Q3 2022 was UBS Group, an estimated $12.7K sold.
Based on aggregated 13F filings for Q3 2022.